Physician profile
John A Williams
NPI 1447214762
$5,881.70
in general payments reported to CMS, 2019-2025
33 companies · $33.21 in 2025
The $33.21 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,538 · 2020: $353 · 2021: $350 · 2022: $862 · 2023: $518 · 2024: $2,228 · 2025: $33.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,589 · Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,589.48 |
| Food and Beverage | $1,189.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,403.41 | 2021-2024 | Micra, Onyx Frontier, Hawkone |
| Medtronic Vascular, INC. | $859.99 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $427.94 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $268.92 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $195.92 | 2021-2023 | Verquvo |
| Shockwave Medical, INC | $185.80 | 2020-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $176.90 | 2019-2023 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $143.51 | 2019-2023 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $130.23 | 2021-2022 | |
| Amgen INC. | $130.17 | 2019-2023 | Repatha |
| Opsens INC. | $116.99 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.16 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $93.12 | 2019-2023 | |
| Pfizer INC. | $88.78 | 2019-2022 | |
| Amarin Pharma, INC. | $72.35 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Infobionic, INC | $68.41 | 2024 | Mome Device |
| Irhythm Technologies, INC. | $66.67 | 2022-2023 | Zio Xt Patch |
| Braemar Manufacturing, LLC | $40.93 | 2019 | |
| Cardiovascular Systems INC. | $39.45 | 2021-2022 | |
| Esperion Therapeutics, INC. | $34.11 | 2021-2023 | Nexletol |
| Penumbra, INC. | $33.74 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.07 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.94 | 2022 | |
| Cardinal Health 200 LLC | $19.85 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.68 | 2025 | Caplyta |
| Lundbeck LLC | $18.91 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.80 | 2023 | Arcalyst |
| Philips North America LLC | $16.85 | 2023 | |
| Elutia, INC. | $13.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.62 | 2020 | |
| Ge Healthcare | $12.11 | 2021 | |
| Astellas Pharma US INC | $11.58 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.